Evidence map›Paper›PMID 41091129›Full record

ArticleThe Journal of experimental medicine2026

FCRL3 is an immunoregulatory receptor that restrains the activation of human memory T lymphocytes.

Niccolò Bianchi, Elena Foli, Mehrpouya Mostanfar, Roberta Marzi, Mara Cetty Spinella, Sara Polletti, Matteo Pecoraro, Antonino Cassotta, Roshan Thakur, David Jarrossay and 3 more

Abstract read
In one paragraph

Article in The Journal of experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Niccolò Bianchi *Institute for Research in Biomedicine, Università della Svizzera italiana , Bellinzona, Switzerland.ORCID 0000-0001-5605-3425
Elena Foli *Institute for Research in Biomedicine, Università della Svizzera italiana , Bellinzona, Switzerland.ORCID 0009-0003-3916-1653
Mehrpouya Mostanfar *Institute for Research in Biomedicine, Università della Svizzera italiana , Bellinzona, Switzerland.ORCID 0000-0003-2624-7063
Roberta MarziInstitute for Research in Biomedicine, Università della Svizzera italiana , Bellinzona, Switzerland.ORCID 0000-0002-3501-4168
Mara Cetty SpinellaInstitute for Research in Biomedicine, Università della Svizzera italiana , Bellinzona, Switzerland.ORCID 0000-0002-2363-3295
Sara PollettiDepartment of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.ORCID 0000-0002-5433-0502
Matteo PecoraroInstitute for Research in Biomedicine, Università della Svizzera italiana , Bellinzona, Switzerland.ORCID 0009-0002-8105-9671
Antonino CassottaInstitute for Research in Biomedicine, Università della Svizzera italiana , Bellinzona, Switzerland.ORCID 0000-0001-8674-4294
Roshan ThakurInstitute for Research in Biomedicine, Università della Svizzera italiana , Bellinzona, Switzerland.ORCID 0000-0001-5284-4975
David JarrossayInstitute for Research in Biomedicine, Università della Svizzera italiana , Bellinzona, Switzerland.ORCID 0000-0002-0924-6395
Federica SallustoInstitute for Research in Biomedicine, Università della Svizzera italiana , Bellinzona, Switzerland.ORCID 0000-0003-3750-2752
Gioacchino NatoliDepartment of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.ORCID 0000-0003-0711-2411
Silvia MonticelliInstitute for Research in Biomedicine, Università della Svizzera italiana , Bellinzona, Switzerland.ORCID 0000-0002-5909-8802

Funding

Ceresio Foundation Lugano, SwitzerlandIstituto Europeo di OncologiaItalian Ministry of HealthScientific Institute for Research, Hospitalization and HealthcareSwiss National Science Foundation 310030_205197
6 · The paper itself

Abstract

Genetic variants in the FCRL3 gene are linked to autoimmune disorders. However, the functional properties of FCRL3-expressing T lymphocytes, and the regulation and functional impact of FCRL3 expression remain understudied. Here, we performed a multiomic and functional analysis of human T lymphocytes expressing FCRL3. FCRL3 expression correlated with reduced capacity of T cells to undergo activation and was accompanied by functional specialization toward a cytotoxic phenotype, resembling cytotoxic CD4+ T lymphocytes and CD8+ effector memory TEMRA cells. FCRL3 expression was induced upon repetitive TCR engagement, and sufficed to attenuate T cell responses, indicating a role as a negative regulator of the activation of differentiated T cell subsets with high cytotoxic capacity. Mechanistically, the cytoplasmic domain of FCRL3 engaged inhibitory molecules, suggesting a direct role in limiting activating signals. Overall, our study establishes FCRL3 as a functional immunoregulatory receptor that restrains the activation of highly specialized human memory T cells.

Indexed as

Immunologic MemoryLymphocyte ActivationMemory T CellsReceptors, ImmunologicCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesHumansReceptors, Antigen, T-CellFCRL3 protein, humanReceptors, Antigen, T-CellReceptors, Immunologic

Identifiers

PMID41091129
PMCPMC12524113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.